Outcomes of Biological Therapy on Rheumatoid Arthritis

Outcomes of Different Biological Therapy on Rheumatoid Arthritis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05267431

Enrollment

200

Registered

2022-03-04

Start date

2022-06-30

Completion date

2023-10-31

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Keywords

Brief summary

Evaluate effect of biological therapy on activity of RA compared to usual DMARDs

Detailed description

Comparison between RA activity in both groups who recieved biological and DMARDS therapy

Interventions

DRUGBiological Drug

Different biological drugs

Study design

Observational model

OTHER

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* RA patients

Exclusion criteria

* any other connective tissue disease

Design outcomes

Primary

Measure	Time frame	Description
Change in activity of rheumatoid arthritis	After 3 months of treatment	By DAS 28; it include 28 tender and swollen joints, laboratory test (ESR) and visual analogue score, if it higher than 5.1 it mean high disease activity and if lower than 3.2 it mean low activity and consider remission if lower than 2.6

Secondary

Measure	Time frame	Description
Activity of RA	3 months after treatment	MHAQ.scores include questionnaire from eight activities of daily living and range from 0 to 3 and lower scores mean better function state and high scores mean worse function state

Countries

Egypt

Contacts

Primary ContactN M Mansour

nesmamansour971@yahoo.com01004517558

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026